Table 1.
Baseline Characteristics of Unmatched and Matched Cohort
| Variables | PS‐Matched Sample | ||
|---|---|---|---|
| Nonuser | OCA User | P Value | |
| (n = 84) | (n = 21) | ||
| Age at cirrhosis, median (IQR) | 59.0 (13.5) | 60.0 (9.0) | 0.3196 |
| Gender, n (%) | 0.7689 | ||
| Male | 45 (53.6%) | 12 (57.1%) | |
| Female | 39 (46.3%) | 9 (42.9%) | |
| Race/ethnicity, n (%) | 0.6299 | ||
| Black | 4 (4.8%) | 2 (9.5%) | |
| Other | 7 (8.3%) | 1 (4.8%) | |
| White | 73 (86.9%) | 18 (85.7%) | |
| BMI, median (IQR) | 27.5 (7.3) | 26.5 (7.9) | 0.8460 |
| BMI, n (%) | 0.7407 | ||
| Underweight (less than 18.5) | 1 (1.2%) | 1 (4.8%) | |
| Normal weight (18.5 to 25) | 18 (21.4%) | 5 (23.8%) | |
| Overweight (25 to 30) | 34 (40.5%) | 8 (38.1%) | |
| Obese (more than 30) | 31 (36.9%) | 7 (33.3%) | |
| Tobacco use, n (%) | 0.1918 | ||
| Current smoker | 26 (30.9%) | 3 (14.3%) | |
| Former smoker | 25 (29.8%) | 10 (47.6%) | |
| Never smoker | 33 (39.3%) | 8 (38.1%) | |
| AUDIT score 1 year after cirrhosis, n (%) | 0.9999 | ||
| Low | 76 (90.5%) | 19 (90.5%) | |
| High | 8 (9.5%) | 2 (9.5%) | |
| Cirrhosis comorbidity index, n (%) | 0.6511 | ||
| 0 | 20 (23.8%) | 6 (28.6%) | |
| 1 + 0/3 + 1 | 64 (76.2%) | 15 (71.4%) | |
| UDCA responder, n (%) | 0.3480 | ||
| No | 55 (65.5%) | 16 (76.2%) | |
| Yes | 29 (34.5%) | 5 (23.8%) | |
| Portal hypertension at baseline, n (%) | 0.2666 | ||
| Yes | 55 (65.5%) | 12 (57.1%) | |
| No | 29 (34.5%) | 9 (42.9%) | |
| AMA, n (%) | 0.0642 | ||
| Positive | 71 (84.5%) | 14 (66.7%) | |
| Negative | 9 (10.7%) | 6 (28.6%) | |
| Unknown | 4 (4.8%) | 1 (4.8%) | |
| Varices, n (%) | 0.3312 | ||
| Yes | 22 (26.2%) | 9 (42.9%) | |
| No | 58 (69.1%) | 11 (52.4%) | |
| Unknown | 4 (4.8%) | 1 (4.8%) | |
| Cirrhosis diagnosis, n (%) | 0.6798 | ||
| Biopsy proven | 27 (32.1%) | 7 (33.3%) | |
| FibroScan | 3 (3.6%) | ‐ | |
| Abnormal liver imaging | 54 (64.3%) | 14 (66.7%) | |
| AST (IU/mL), median (IQR) | 38.0 (22.5) | 48.0 (17.0) | 0.1255 |
| ALT (IU/mL), median (IQR) | 37.5 (32.5) | 49.0 (27.0) | 0.1266 |
| ALP (IU/mL), median (IQR) | 226.5 (184.0) | 281.0 (187.0) | 0.2067 |
| Albumin (g/dL), median (IQR) | 3.8 (0.5) | 3.8 (0.7) | 0.8353 |
| Platelet count (x10E9/L), median (IQR) | 196.0 (104.5) | 166.0 (97.0) | 0.0987 |
| Serum sodium (mEq/L), median (IQR) | 138.0 (4.0) | 138.0 (3.0) | 0.4766 |
| Creatinine (mg/dL), median (IQR) | 0.9 (0.3) | 0.9 (0.4) | 0.7708 |
| Total bilirubin (mg/dL), median (IQR) | 0.7 (0.4) | 0.9 (0.3) | 0.0505 |
| International normalized ratio, median (IQR) | 1.0 (0.2) | 1.0 (0.1) | 0.3492 |
| CTP score, median (IQR) | 5.0 (0.0) | 5.0 (0.0) | 0.6583 |
| MELD score, median (IQR) | 6.0 (0.0) | 6.0 (0.0) | 0.8925 |
Laboratory tests in the unmatched cohort were those obtained closest to the time of diagnosis of cirrhosis. In the matched cohort, laboratory tests used were those obtained at the time of OCA initiation or “matched OCA date” (matched for time from cirrhosis diagnosis).
Abbreviation: IQR, interquartile range.